Drug intelligence / Profile preview

ACG-701

Development stage: Phase 2
Lead developer: Aceragen
Modality: Small Molecules
Administration: Oral

Overview

ACG-701 is an oral, loading dose formulation of sodium fusidate, an antibiotic effective against *Staphylococcus aureus*, including methicillin-resistant *S. aureus* (MRSA). It is being developed for the treatment of acute pulmonary exacerbations associated with cystic fibrosis and melioidosis. ACG-701 has received Fast Track Designation, Orphan Drug Designation, and Qualified Infectious Disease Product (QIDP) from the FDA for cystic fibrosis.

Brand names: Taksta
Other names: Sodium fusidate

Targets

EF-G (Elongation factor G 1, mitochondrial)

Beyond the preview

Go deeper on ACG-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACG-701.

Explore the full profile